MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
Globe Newswire•03/11/2026•16:40 ET
1
Key Highlights
- ➤MediWound to sell 1,200,000 ordinary shares at $12.50 each
- ➤Gross proceeds expected at approximately $15 million before offering expenses
- ➤Underwriter receives 30-day option for up to 180,000 additional shares
- ➤Net proceeds earmarked for working capital and general corporate purposes
- ➤Offering expected to close on or about November 5, 2026
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,200,000 ordinary shares of MediWound, at a price to the public of $12.50 per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 5, 2026, subject to satisfaction of customary closing conditions.
Get started
Create a free account to read the full story.